Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug shows promise for dangerous low sodium condition

NCT ID NCT04447911

Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study tests whether the diabetes drug empagliflozin (Jardiance) can safely raise low sodium levels in people with certain conditions like SIADH, liver failure, or kidney failure. About 172 adults with chronic low sodium will receive either the drug or a placebo for up to 30 days. The goal is to see if the drug works better than current treatments like fluid restriction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 113 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2021

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- chronic eu- OR hypervolemic non hyperosmolar (\<300 mOsm/kg) hyponatremia (heparin plasma sodium \<135 mmol/L on day of inclusion) Exclusion Criteria: * known hypersensitivity or allergy to class of drugs or the investigational product, * severe symptomatic hyponatremia in need of treatment with 3% NaCl-solution or in need of intensive/intermediate care treatment at time of inclusion * clinical hypovolemia * Severe reduction of eGFR \<20 mL/min/1,73 m2 (KDIGO G4 and G5) or end stage renal disease * Chronic liver insufficiency with Child Pugh Score ≥10 or decompensated liver cirrhosis (jaundice, hepatorenal syndrome, encephalopathy, bleeding, …) * Hepatic impairment defined as aspartate transaminase (AST) or alanine transaminase (ALT) \>3x the upper limit of normal (ULN); or total bilirubin \>2x ULN at time of enrolment * uncontrolled hypothyroidism * uncontrolled adrenal insufficiency * systolic blood pressure \<90mmHg * contraindication for lowering blood pressure * diabetes mellitus type 1 or pancreatic diabetes mellitus * treatment with SGLT2 inhibitors, lithium chloride, vaptans, demeclocycline or urea on inclusion day * severe immunosuppression (leucocytes \<2 G/l) * peripheral arterial disease stage III-IV of the Fontaine Classification * fasting or other reasons preventing medication intake * previous enrolment into the current study * participation in another intervention study * pregnancy, breastfeeding, intention to become pregnant during the course of the study or lack of safe contraception. * end of life care

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Euvolemic hyponatremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyponatremia inappropriate ADH syndrome kidney failure liver failure nephrogenic syndrome of inappropriate antidiuresis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyponatremia Kidney failure Liver failure SIADH

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

  • Erasmus Universität Medisch Centrum Rotterdam, Department of Internal Medicine

    RECRUITING

    Rotterdam, 3015, Netherlands

  • Kantonsspital Luzern

    RECRUITING

    Lucerne, Canton of Lucerne, 6000, Switzerland

  • Spitalzentrum Biel

    RECRUITING

    Biel, 2502, Switzerland

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

  • University Hospital of Würzburg, med. Poliklinik

    RECRUITING

    Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.